ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia

Gene mutations independent of BCR::ABL1 have been identified in newly diagnosed patients with chronic myeloid leukemia (CML) in chronic phase, whereby mutations in epigenetic modifier genes were most common. These findings prompted the systematic analysis of prevalence, dynamics, and prognostic sign...

Descripción completa

Detalles Bibliográficos
Autores principales: Schönfeld, Lioba, Rinke, Jenny, Hinze, Anna, Nagel, Saskia N., Schäfer, Vivien, Schenk, Thomas, Fabisch, Christian, Brümmendorf, Tim H., Burchert, Andreas, le Coutre, Philipp, Krause, Stefan W., Saussele, Susanne, Safizadeh, Fatemeh, Pfirrmann, Markus, Hochhaus, Andreas, Ernst, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9417980/
https://www.ncbi.nlm.nih.gov/pubmed/35902731
http://dx.doi.org/10.1038/s41375-022-01648-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9417980/
https://www.ncbi.nlm.nih.gov/pubmed/35902731
http://dx.doi.org/10.1038/s41375-022-01648-4

Ejemplares similares